Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new?-Reference-Cited by-同舟云学术

Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new?

Published:2023-05 Issue:5 Volume:110 Page:552-559
ISSN:0007-4551
Container-title:Bulletin du Cancer
language:en
Short-container-title:Bulletin du Cancer

Author:

Coutzac Clélia,Funk-Debleds Paméla,Cattey-Javouhey Anne,Desseigne Françoise,Guibert Pierre,Marolleau Pauline,Rochefort Pauline,de la Fouchardière Christelle

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Reference66 articles.

1. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas;Sakai;J Natl Cancer Inst,1986

2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

3. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer;Van Cutsem;Gastric Cancer,2015

4. Assessment of a HER2 scoring system for gastric cancer: results from a validation study;Hofmann;Histopathology,2008

5. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab;Tanner;Ann Oncol,2005

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving individualised therapies in localised gastro-oesophageal adenocarcinoma;The Lancet Oncology;2024-09

2. Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment;International Journal of Biological Sciences;2024

3. Histopathological Aspects of the Prognostic Factors for Salivary Gland Cancers;Cancers;2023-02-15